



مركز الكويت لمكافحة السرطان  
Kuwait Cancer Control Center

## NIVolumab / IPILImumab (Pleural mesothelioma)



\* N I V I P I - 0 0 - 0 6 - C N - T X \*



Ministry of Health

Name:

File #:

Ht (cm):

Nationality:

Civil ID:

Wt (Kg):

Gender/Age:

DOB:

BSA (m<sup>2</sup>):

Indication(s): Relapsed malignant pleural mesothelioma.

Central line:  Available  NA

Allergies:  NKA  Yes, specify; \_\_\_\_\_

Parameters: Initiate treatment only if ANC  $\geq$  1000; HB  $\geq$  80; Plt  $\geq$  100,000; CrCl  $>$  45 ml/min.

Pre-treatment Medications: (30-60 min before starting treatment)

Chlorphenamine 10 mg PO/IV

### Standard Protocol:

DRUG	DOSE	ADMINISTRATION	DAYS
NIVolumab	3 mg/kg	IV in 100 mL NS over 60 min.	D1, 15, 29
IPILImumab	1 mg/kg	IV in 100 mL NS over 60 min.	D1
<b>To be repeated every 6 weeks until disease progression or intolerable toxicity.</b>			

### Treatment Description:

Cycle	Day	Date	NIVolumab	IPILImumab	Physician	Consultant
C# __	D1					
	D15			XXXXXXXX		
	D29			XXXXXXXX		

Cycle	Day	Date	NIVolumab	IPILImumab	Physician	Consultant
C# __	D1					
	D15			XXXXXXXX		
	D29			XXXXXXXX		

### Important Notes:

Reported grade 3/4 toxicities:  None  Hematological  Non-Hematological

If yes; Did it indicate hospitalization?  Yes  No

Did it indicate chemo-delay for  $\geq$  7 days?  Yes  No

Did it indicate dose reduction?  Yes  No

Did it indicate G-CSF support?  Yes  No